U.S. sets global benchmark for COVID-19 vaccine price at around the cost of a flu shot


  • World
  • Thursday, 23 Jul 2020

FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) - The U.S. government has set a benchmark for COVID-19 vaccine pricing in a $2 billion deal announced on Wednesday with Pfizer Inc and German biotech BioNTech SE that will likely pressure other manufacturers to set similar prices, industry analysts told Reuters.

The deal, which is contingent on an approvable product, secures enough vaccine to inoculate 50 million Americans for about $40 a person, or about the cost of annual flu shots, and is the first to provide a direct window into likely pricing of successful COVID-19 vaccines.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

Senegal president's Pastef party wins 130 out of 165 seats in legislative vote, state TV says
Kenya axes airport expansion, power transmission deals with Indian firm
China Telecom launches Saudi subsidiary
FBI, DHS leaders decline to testify publicly about threats facing US
AU, UN agencies call for building resilient industries to advance Africa's development
115 suspected terrorists killed in northern Nigeria: military
Bolsonaro knew of plot to kill Lula, Brazil police find, CNN Brasil says
Journalist seized in Turkmenistan ahead of Swiss award ceremony, say rights groups
South Africa declares food-borne illnesses a national disaster
Romania's radical right leader Simion, a Trump fan, sets eyes on presidency

Others Also Read